BioGaia’s profit for third quarter to exceed market expectations

Report this content

(Figures in brackets refer to the year-earlier period)

In the latter part of the third quarter of 2021, BioGaia was requested by certain customers at risk of running out of stock to bring orders forward, which has had a positive impact on sales for the quarter.

Sales for the third quarter are preliminarily estimated at SEK 174 million (132), up 32%. Operating profit for the third quarter is preliminarily estimated at SEK 67 million (27), up 148%. Full-year sales are largely expected to be in line with expectations.

BioGaia will publish the interim report for the third quarter on Thursday, 21 October 2021 at 8:00 a.m., followed by a teleconference at 9:30 a.m.

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the CEO, on 13-10-2021 21:00 CET.

For additional information please contact
Isabelle Ducellier, CEO: +46 8 555 293 00

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm.​​​​​​​